The ongoing Finnish cardiovascular disease research concentrates mainly on blood pressure, coronary artery and cardiac impairment. The different branches of research focus on cell biology.
The strongest areas of research include:
- Cardiac impairment research with a cardiac stimulant like levosimendan
- α-receptor research in companies and at the University of Turku
- Research into vascular diseases, as well as heart and vascular growth factors, such as vascular endothelial growth factor (VEGF), at the University of Eastern Finland
Levosimendan is an excellent example of Finnish scientific and commercial success in the field of cardiovascular disease. Levosimendan is a calcium sensitizer developed by the Orion Corporation, which is used in the management of acutely decompensated congestive heart failure.
Looking to the future, the best possibilities for cardiovascular developments lie in remote diagnostics, for example mobile sensor-based technologies, as well as in new imaging possibilities in diagnosis and R&D and the cultivation of tissue structures, such as heart valves and blood vessels.
The following links include some examples of organizations with cardiovascular disease expertise in Finland: